La cadena de opciones muestra datos clave de las opciones de acciones de Scinai Immunotherapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Scinai Immunotherapeutics..

Scinai Immunotherapeutics (NASDAQ:SCNI) Bolsa, Cadena de Opciones

Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics Ltd

Press Releases

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Small Cap

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Earnings

Scinai Announces Annual Financial Results for 2024

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

SCNI

Aditxt

AIM ImmunoTech

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

BriaCell Therapeutics

bioAffinity Technologies

Celularity

CERo Therapeutics Holdings, Inc. - Warrants

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Cyclacel Pharmaceuticals

Entero Therapeutics

GRI Bio

Lixte Biotechnology Holdings, Inc. - Warrants

Lixte Biotechnology

Medicus Pharma

Oragenics

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revolution Medicines

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Comments

Scinai Immunotherapeutics

Scinai Immunotherapeutics (SCNI) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL